PHOTO: Martina Kovarova, PhD, EFDA said preventing oral and vaginal HIV - transmission in preclinical models. more Credit: David Kinton, ...
PHOTO: Martina Kovarova, PhD, EFDA said preventing oral and vaginal HIV - transmission in preclinical models. more
Credit: David Kinton, UNC School of Medicine
Chapel Hill, North Carolina - HIV remains a major health problem for women and children worldwide. Worldwide occur most new HIV infections in young women. Each year 1.5 million women living with HIV, are pregnant. Without effective treatment, up to 45 percent of mothers with HIV to transmit the virus to her child, usually through breastfeeding. In an effort to prevent the transmission of HIV to women and their children, researchers at the University of North Carolina at Chapel Hill have shown the efficacy of a new drug against HIV, 4'-ethynyl-2-fluoro-2 'deoxyadenosine or EFDA , in preclinical animal models. They found that EFDA vaginal and oral transmission of HIV to prevent. These Results 1. August, in the Journal of Antimicrobial Chemotherapy on Monday released
"Women and children are vulnerable to HIV infection," said Martina Kovarova, PhD, lead author of the study and assistant professor of medicine in the Division of Infectious Diseases, Faculty of Medicine, Professor UNC. "We discovered that EFDA vaginal transmission of HIV to prevent, prevent new infections in women. In addition, we could also show that EFDA can prevent oral transmission of HIV prevent babies of mothers born already with HIV contract the virus during breastfeeding . "
Kovarova and colleagues tested the efficacy of the EFDA in vivo humanized validated preclinical vaginal and oral transmission of HIV using mouse models. a dose daily to prevent even EFDA able HIV infection in mice that were repeatedly exposed to high doses of HIV in both studies.
"Our results are very encouraging," Kovarova said. "Now we will try to determine how a low dose can be administered, while offering protection against HIV, and how long the drug will last in your system to see if a daily dose is required, or if you lot can treat rare. "
"Most new HIV infections in women and children occur in countries with limited resources to develop. The availability of anti-HIV drug that is strong enough to be used as a preventive agent in women and children have the potential to make a to have significant impact on the global HIV epidemic, "said Angela choice, PhD, lead author of the study and a medical assistant in the department of infectious diseases, Faculty of medicine, Professor UNC.
###
The National Institute of Allergy and Infectious Diseases, National Institutes of Health funded this study.
The mission of the Institute of UNC for Global Health and Infectious Diseases is to use all the resources of the university and its partners to solve global health problems, reduce the burden of disease and maintain the next generation of world leaders in health. More information at http: // www. Lipolysis unc edu .. ,
Disclaimer: AAAS and EurekAlert! You are not responsible for the accuracy of press releases on EurekAlert date! Facilities or contribute to the use of information through the EurekAlert system.
